Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations.

Svartz, Nanna

doi:10.1111/j.0954-6820.1942.tb06841.x

Cited by 304 publications

(37 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sulfasalazine (1942) 17 was expanded by corticosteroids (1955), 18 mercaptopurine and precursor azathioprine (1962), 19,20 mesalazine (1977), 21 cyclosporine A, tacrolimus, and infliximab. 1,3 The efficiency of each these medications has been confirmed by randomized clinical studies and recommendations have been made for single indications and groups within IBD.…”

Section: Discussionmentioning

confidence: 99%

Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis

Swidsinski

Loening‐Baucke

Bengmark

et al. 2007

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis

Swidsinski

Loening‐Baucke

Bengmark

et al. 2007

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…2 The covalent link of sulfapyridine and salicylate through an azo-bond was designed for combining the antibacterial activity of sulfapyridine together with the antiinflammatory properties of salicylates while reducing gastric irritation. 2 Since then aminosalicylates became the most important drugs for UC both for induction and maintenance of remission. In recent years 5-ASA's preventive activity against colitis-associated cancer became apparent.…”

Section: Keymentioning

confidence: 99%

The position of the amino group on the benzene ring is critical for mesalamineʼs improvement of replication fidelity

Campregher

Luciani

Biesenbach

et al. 2010

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…[1] Sulfasalazine has become, because of empirically observed clinical efficacy, “the most common medicine used to treat “Inflammatory” Bowel Disease (IBD) [2] with greatest efficacy in ulcerative colitis. [3]–[5] …”

Section: Introductionmentioning

confidence: 99%

On the Action of 5-Amino-Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis

Greenstein¹,

Su²,

Shahidi³

et al. 2007

PLoS ONE

View full text Add to dashboard Cite

BackgroundIntroduced in 1942, sulfasalazine (a conjugate of 5-aminosalicylic acid (5-ASA) and sulfapyridine) is the most prescribed medication used to treat “inflammatory” bowel disease (IBD.) Although controversial, there are increasingly compelling data that Mycobacterium avium subspecies paratuberculosis (MAP) may be an etiological agent in some or all of IBD. We have shown that two other agents used in the therapy of IBD (methotrexate and 6-MP) profoundly inhibit MAP growth. We concluded that their most plausible mechanism of action is as antiMAP antibiotics. We herein hypothesize that the mechanism of action of 5-ASA and/or sulfapyridine may also simply be to inhibit MAP growth.MethodologyThe effect on MAP growth kinetics by sulfasalazine and its components were evaluated in bacterial culture of two strains each of MAP and M. avium, using a radiometric (14CO2 BACTEC®) detection system that quantifies mycobacterial growth as arbitrary “growth index units” (GI). Efficacy data are presented as “percent decrease in cumulative GI” (%−ΔcGI).Principal FindingsThere are disparate responses to 5-ASA and sulfapyridine in the two subspecies. Against MAP, 5-ASA is inhibitory in a dose-dependent manner (MAP ATCC 19698 46%−ΔcGI at 64 µg/ml), whereas sulfapyridine has virtually no effect. In contrast, against M. avium ATCC 25291, 5-ASA has no effect, whereas sulfapyridine (88%−ΔcGI at 4 µg/ml) is as effective as methotrexate, our positive control (88%−ΔcGI at 4 µg/ml). Conclusions5-ASA inhibits MAP growth in culture. We posit that, unknowingly, the medical profession has been treating MAP infections since sulfasalazine's introduction in 1942. These observations may explain, in part, why MAP has not previously been identified as a human pathogen. We conclude that henceforth in clinical trials evaluating antiMAP agents in IBD, if considered ethical, the use of 5-ASA (as well as methotrexate and 6-MP) should be excluded from control groups.

show abstract

Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations.

Cited by 304 publications

References 2 publications

Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis

Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis

The position of the amino group on the benzene ring is critical for mesalamineʼs improvement of replication fidelity

On the Action of 5-Amino-Salicylic Acid and Sulfapyridine on M. avium including Subspecies paratuberculosis

Contact Info

Product

Resources

About